Condition: Cardiotoxicity Induced by Drug Therapy for Breast Cancer · Sponsor: Zhejiang Cancer Hospital
To evaluate the effectiveness and safety of Shengmai San in preventing anthracycline sequential trastuzumab therapy related cardiac toxicity through a prospective randomized controlled study.
This description comes directly from the study's public registry record.
Ping Huang · +8613685766632 · zlyyhp@163.com
Zhanhong Chen · +8613606505124 · czred@sina.com
Always discuss trial participation with your own doctor first.
| Zhejiang Cancer Hospital | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06214195